{"id":40703,"date":"2026-01-22T05:38:34","date_gmt":"2026-01-22T05:38:34","guid":{"rendered":"https:\/\/allonlinebanglanewspapers.com\/news\/new-nanoparticle-technology-offers-hope-for-hard-to-treat-diseases\/"},"modified":"2026-01-22T05:38:34","modified_gmt":"2026-01-22T05:38:34","slug":"new-nanoparticle-technology-offers-hope-for-hard-to-treat-diseases","status":"publish","type":"post","link":"https:\/\/allonlinebanglanewspapers.com\/news\/new-nanoparticle-technology-offers-hope-for-hard-to-treat-diseases\/","title":{"rendered":"New nanoparticle technology offers hope for hard-to-treat diseases"},"content":{"rendered":"
\n

Sydney, Australia, Jan. 21, 2026 (GLOBE NEWSWIRE) — A newly published paper in Nature Nanotechnology details groundbreaking nanoparticle technology, with research led by University of Technology<\/strong> Chair Professor in Nanomedicine Bingyang Shi.<\/p>\n

A newly published perspective article in\u00a0Nature Nanotechnology<\/em><\/a>\u00a0details groundbreaking nanoparticle technology to eliminate harmful, disease-causing proteins in the body. The technology marks a transformative leap in the potential to drug \u201cundruggable\u201d proteins, to treat diseases such as dementia and brain cancer.<\/p>\n

The research was led by\u00a0Chair Professor in Nanomedicine Bingyang Shi<\/a>\u00a0from the University of Technology Sydney (UTS), together with international collaborators Professor Kam Leong from Columbia University, and Professor Meng Zheng from Henan University.<\/p>\n

\u201cProteins are essential for nearly every function in the body, but when they become mutated, misfolded, overproduced, or build up in the wrong place, they can disrupt normal cell processes and trigger disease,\u201d said Professor Shi.<\/p>\n

\u201cMany conditions, including cancer, dementia and autoimmune disorders, are driven by abnormal proteins, and some have shapes or behaviours that make them particularly resistant to drug treatments.\u201d<\/p>\n

The researchers developed a new class of engineered nanoparticles, known as nanoparticle-mediated targeting chimeras (NPTACs). These tiny particles can be customised to bind to, and degrade, specific disease-related proteins.<\/p>\n

The\u00a0Nature Nanotechnology<\/em>\u00a0article,\u00a0Nanoparticle-mediated targeting chimeras transform targeted protein degradation<\/a>, examines the new technology and potential applications. The initial discovery was also published in\u00a0Nature Nanotechnology<\/em><\/a>\u00a0in October 2024.<\/p>\n

\u201cWe have developed an efficient and flexible method to guide disease-causing proteins, whether inside or outside the cell, into the body\u2019s natural recycling system, where they can be broken down and removed,\u201d said Professor Shi.<\/p>\n

Targeted protein degradation is one of the fastest-growing areas in biotechnology, with immense commercial potential. Industry leaders such as Arvinas have raised over $1 billion USD and struck multi-billion-dollar partnerships with Pfizer, Bayer, and Roche.<\/p>\n

However, conventional targeted protein degradation tools are limited by poor tissue penetration, off-target effects, and synthetic complexity \u2013 challenges that have hindered applications in areas such as brain disease and solid tumors.<\/p>\n

\u201cOur nanoparticle-based strategy overcomes these bottlenecks,\u201d said Professor Shi.<\/p>\n

Key advantages of the new technology include:<\/strong><\/p>\n

\u00a0 \u00a0 Enabling degradation of both intra- and extracellular proteins<\/p>\n

\u00a0 \u00a0 Tissue- and disease-specific targeting, including across the blood\u2013brain barrier<\/p>\n

\u00a0 \u00a0 Plug-and-play modularity, enabling rapid adaptation to diverse protein targets<\/p>\n

\u00a0 \u00a0 Scalable and clinically translatable; leverages FDA-approved nanomaterials & industry-proven strategies<\/p>\n

\u00a0 \u00a0 Multifunctional integration, can combine with diagnostic or therapeutic capabilities.<\/p>\n

Protected by multiple international patents, NPTACs have already shown strong preclinical results against key disease targets such as EGFR (a protein often driving tumour growth) and PD-L1 (a protein that helps cancer cells evade the immune system).<\/p>\n

\u201cThis progress paves the way for applications in oncology, neurology and immunology. It changes how we think about nanoparticles \u2013 not only as delivery tools but also as active therapeutic agents,\u201d said Professor Shi.<\/p>\n

\u201cWith the targeted protein degradation market expected to surpass $10 billion USD by 2030, NPTACs provide a powerful platform for the next generation of smart, precision therapies.<\/p>\n

“We are now seeking strategic industry partners to accelerate clinical development, license applications across therapeutic fields, and prepare for regulatory approval,” he said.<\/p>\n\n <\/div>\n","protected":false},"excerpt":{"rendered":"

Sydney, Australia, Jan. 21, 2026 (GLOBE NEWSWIRE) — A newly published paper in Nature Nanotechnology details groundbreaking nanoparticle technology, with research led by University of Technology Chair Professor in Nanomedicine Bingyang Shi. A newly published perspective article in\u00a0Nature Nanotechnology\u00a0details groundbreaking nanoparticle technology to eliminate harmful, disease-causing proteins in the body. The technology marks a transformative […]<\/p>\n","protected":false},"author":2,"featured_media":40704,"comment_status":"","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"fifu_image_url":"https:\/\/ml.globenewswire.com\/Resource\/Download\/ffd33cd0-203f-4184-bce7-72503fd19ee3","fifu_image_alt":"","footnotes":""},"categories":[11],"tags":[],"class_list":["post-40703","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-globenewswire"],"acf":[],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/allonlinebanglanewspapers.com\/news\/wp-json\/wp\/v2\/posts\/40703","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/allonlinebanglanewspapers.com\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/allonlinebanglanewspapers.com\/news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/allonlinebanglanewspapers.com\/news\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/allonlinebanglanewspapers.com\/news\/wp-json\/wp\/v2\/comments?post=40703"}],"version-history":[{"count":0,"href":"https:\/\/allonlinebanglanewspapers.com\/news\/wp-json\/wp\/v2\/posts\/40703\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/allonlinebanglanewspapers.com\/news\/wp-json\/wp\/v2\/media\/40704"}],"wp:attachment":[{"href":"https:\/\/allonlinebanglanewspapers.com\/news\/wp-json\/wp\/v2\/media?parent=40703"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/allonlinebanglanewspapers.com\/news\/wp-json\/wp\/v2\/categories?post=40703"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/allonlinebanglanewspapers.com\/news\/wp-json\/wp\/v2\/tags?post=40703"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}